Resource Library Search

Resource Library Search Filter

Filter By Resource Library: Format Type

Journal Article (38)

Podcast (10)

Guidelines (7)

Website (6)

CME (2)

Filter By Resource Library: Topic

Treatment (64)

Learn (62)

Prepare the Care Team (52)

Treatment Decision-Making (36)

Lay the Groundwork (34)

Multiple Myeloma (22)

B-cell ALL (20)

Implement the Initiative (17)

Clinical Trials (14)

Timing of MRD Testing (12)

CLL (10)

Assess (7)

MRD Testing Methods (2)

Resource Library Search

You searched for:

Treatment

Displaying results 21 - 40 of 64

Hematopoietic stem cell involvement in BCR-ABL1�positive ALL as a potential mechanism of resistance to blinatumomab therapy

BCR-ABL1�positive cells outside the B-lineage compartment are found in 40% of adult patients with BCR-ABL1�positive BCP-ALL. Selection of preexisting CD19� subclones is a potential source of tumor escape after CD19-targeted therapies in adult Philadelphia chromosome�positive ALL.

Blood

B-cell ALL Clinical Trials Lay the Groundwork Learn Prepare the Care Team Treatment Journal Article

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Among adults with MRD-positive ALL in hematologic remission after chemotherapy, 78% achieved a complete MRD response with blinatumomab...Complete MRD response after blinatumomab treatment in this population was associated with significantly improved OS.

Blood

B-cell ALL Lay the Groundwork Learn Prepare the Care Team Treatment Journal Article

NCCN Guidelines for Multiple Myeloma

NCCN offers clinical guidelines to guide the treatment and care of patients with multiple myeloma. (Create a free account profile to access guidelines.)

National Comprehensive Cancer Network (NCCN)

Assess Implement the Initiative Lay the Groundwork Learn Multiple Myeloma Prepare the Care Team Treatment Treatment Decision-Making Guidelines

NCCN Guidelines for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCCN offers clinical guidelines to guide the treatment and care of patients with CLL. (Create a free account profile to access guidelines.)

National Comprehensive Cancer Network (NCCN)

Assess CLL Implement the Initiative Lay the Groundwork Learn Prepare the Care Team Treatment Treatment Decision-Making Guidelines

NCCN Guidelines for Acute Lymphoblastic Leukemia

NCCN offers clinical guidelines to guide the treatment and care of patients with ALL. (Create a free account profile to access guidelines.)

National Comprehensive Cancer Network (NCCN)

Assess B-cell ALL Implement the Initiative Lay the Groundwork Learn Prepare the Care Team Treatment Treatment Decision-Making Guidelines

A Glimpse Into the Future of Myeloma Patient Management

This online, no-cost CME activity, features presentations on current and evolving MM patient care practices and discussions of how they are likely to evolve over the next 3 to 5 years.

Multiple Myeloma Research Foundation (MMRF)

Learn Multiple Myeloma Prepare the Care Team Treatment Treatment Decision-Making CME

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

"Adults with relapsed or refractory B-precursor acute lymphoblastic leukaemia have an unfavourable prognosis... This study aimed to confirm the activity and safety profile of blinatumomab for ALL."

The Lancet Oncology

Learn Prepare the Care Team Treatment Journal Article

Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia

"Initial imatinib-based therapy of Ph+ adult ALL is associated with lower early mortality and higher CR rate. In adults with Ph+ ALL, allogeneic SCT in first CR prolongs relapse-free survival and OS."

Blood

Lay the Groundwork Learn Prepare the Care Team Treatment Journal Article

NCCN Guidelines for Acute Lymphoblastic Leukemia

NCCN offers clinical guidelines to guide the treatment and care of patients with ALL.

National Comprehensive Cancer Network (NCCN)

Assess Implement the Initiative Lay the Groundwork Learn Prepare the Care Team Treatment Treatment Decision-Making Guidelines

Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT

"Assessment of measurable residual disease (MRD) is rapidly transforming the therapeutic and prognostic landscape of a wide range of hematological malignancies. Its prognostic value in acute lymphoblastic leukemia (ALL) has been established and MRD measured at the end of induction is increasingly used to guide further therapy. Although MRD detectable immediately before allogeneic hematopoietic cell transplantation (HCT) is known to be associated with poor outcomes, it is unclear if or to what extent this differs with different types of conditioning."

Journal of Hematology & Oncology

Lay the Groundwork Learn Timing of MRD Testing Treatment Treatment Decision-Making Journal Article

Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment

"Ten of 36 patients (28%) achieved an OS ?30 months in a blinatumomab study in relapsed/refractory acute lymphoblastic leukemia. Long-term survival may be associated with T-cell expansion, B-cell depletion, and a minimal residual disease response."

Blood

Lay the Groundwork Learn Prepare the Care Team Treatment Journal Article

Hematopoietic stem cell involvement in BCR-ABL1�positive ALL as a potential mechanism of resistance to blinatumomab therapy

"BCR-ABL1�positive cells outside the B-lineage compartment are found in 40% of adult patients with BCR-ABL1�positive BCP-ALL. Selection of preexisting CD19� subclones is a potential source of tumor escape after CD19-targeted therapies in adult Philadelphia chromosome�positive ALL."

Blood

Lay the Groundwork Learn Prepare the Care Team Treatment Journal Article

Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia

"Authors identified genetic mutations in�CD19�and loss of heterozygosity at the time of CD19��relapse to chimeric antigen receptor (CAR) therapy."

Nature Medicine

Learn Prepare the Care Team Treatment Journal Article

Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions

"This comprehensive review focuses on the recent advances and future directions in novel therapeutic strategies in adult ALL."

Journal of Hematology & Oncology

Learn Prepare the Care Team Timing of MRD Testing Treatment Treatment Decision-Making Journal Article

Differential impact of minimal residual disease negativity according to salvage status in patients with relapsed/refractory B cell acute lymphoblastic leukemia

"In adults with relapsed/refractory ALL receiving first salvage therapy, achievement of MRD negativity is an important therapeutic outcome. Patients who achieve MRD negativity with first salvage treatment and undergo SCT have the best long-term survival."

Cancer

Lay the Groundwork Learn Treatment Treatment Decision-Making Journal Article

CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD)

This analysis is based on a phase 2 study...investigating the combination of low-intensity chemotherapy (mini-hyper-CVD) in combination with INO with or without blinatumomab in patients with R-R ALL.

62nd ASH Annual Meeting and Exposition

Learn Prepare the Care Team Treatment

CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy

Preinfusion dim CD19 expression and rare CD19� events in B-ALL do not affect relapses or responses to CD19-directed CAR T-cells... Prior blinatumomab treatment increases the rate of failure to achieve MRD� remission and CD19� MRD and relapse.

Blood Advances

Lay the Groundwork Learn Prepare the Care Team Treatment Journal Article

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

"Among adults with MRD-positive ALL in hematologic remission after chemotherapy, 78% achieved a complete MRD response with blinatumomab... Complete MRD response after blinatumomab treatment in this population was associated with significantly improved OS."

Blood

Lay the Groundwork Learn Prepare the Care Team Treatment Journal Article

Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ�)

Health Professional Version

National Cancer Institute